Summary
Candesartan Cilexetil has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Kidney Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Kidney Disease. ClinicalTrials.gov lists 8 registered trials linking Candesartan Cilexetil to Chronic Kidney Disease: 1 is active or not yet recruiting; 5 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00741585). It plans or enrolled 21983 participants. Registration activity spans 2005 to 2026. No published literature item is linked to Candesartan Cilexetil and Chronic Kidney Disease in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Chronic Kidney Disease ranks 534 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: GFR decline averages 2-5 mL/min/year on standard care (ACE/ARB + blood pressure control); progression to end-stage renal disease (ESRD) in ~20-30% at 10 years for moderate CKD; reversal essentially impossible once structural fibrosis established.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 45.0 (trials 25.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 1 active / not yet recruiting, 5 completed, 2 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor; inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | AGTR1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00741585 | Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment 2008 | completed | Phase 4 | 21,983 |
| NCT01827202 | RAS Quantification in Patients With Aliskiren or Candesartan 2012 | completed | Phase 4 | 24 |
| NCT07547878 | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) 2026 | not yet recruiting | Phase 4 | 64 |
| NCT01377285 | Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) 2010 | status unknown | Phase 4 | 350 |
| NCT01976572 | Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects 2013 | completed | Phase 1 | 18 |
| NCT01678794 | CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function 2012 | completed | PHASE1, PHASE2 | 33 |
| NCT00231803 | The Canadian Prevention of Renal and Cardiovascular Endpoints Trial 2005 | completed | Not applicable | 474 |
| NCT05271448 | Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography 2021 | status unknown | Not applicable | 600 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: inhibitor; inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Candesartan Cilexetil approved for Chronic Kidney Disease?
Candesartan Cilexetil has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Kidney Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Kidney Disease. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Candesartan Cilexetil in clinical trials for Chronic Kidney Disease?
ClinicalTrials.gov lists 8 registered trials linking Candesartan Cilexetil to Chronic Kidney Disease: 1 is active or not yet recruiting; 5 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00741585). It plans or enrolled 21983 participants. Registration activity spans 2005 to 2026.
What does the evidence show for Candesartan Cilexetil in Chronic Kidney Disease?
Candesartan Cilexetil has 5 completed registered trials for Chronic Kidney Disease but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.